IHS Chemical Week

EnviroTech :: Innovation

Lonza to Supply Commercial Volumes of Antibody Drug

4:57 AM MST | November 10, 2009 | Alex Scott

Lonza has disclosed that GlaxoSmithKline (GSK) and Genmab’s antibody drug Arzerra, for treating chronic lymphocytic leukemia (CLL), will be manufactured by Lonza. Arzerra, also known as ofatumumab, is a monoclonal antibody. The drug recently has been approved by the U.S. FDA. Lonza carried out process development and cGMP manufacturing services associated with the production of the drug. Lonza says it will supply the drug under the terms of a long-term supply agreement. Financial details were not disclosed.   Some analysts suggest sales of the drug for...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa